Drug Search Results
More Filters [+]

Tonogenchoncel-L

Alternative Names: Tonogenchoncel-L, Invossa, Tissuegene-Cs INVOSSA, tissuegene-c, tg-c
Latest Update: 2024-07-11
Latest Update Note: News Article

Product Description

Its novel osteoarthritis drug, TG-C, is designed to conveniently and effectively treat osteoarthritis of the knee by reducing pain, increasing function and slowing the progression of the disease without the side effects usually seen with other palliative options such as NSAIDs or steroids.

Mechanisms of Action: Cell Therapy,TGFb

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Kolon Life Science
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tonogenchoncel-L

Countries in Clinic: United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Osteoarthritis

Phase 2: Osteoarthritis, Hip

Phase 1: Back Pain|Intervertebral Disc Degeneration|Spinal Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TGC-DDD-101

P1

Not yet recruiting

Back Pain|Intervertebral Disc Degeneration|Spinal Diseases

2027-11-01

43%

TGC-OAH-201

P2

Not yet recruiting

Osteoarthritis, Hip

2025-10-01

24%

TGC-12301

P3

Active, not recruiting

Osteoarthritis

2024-06-04

34%

TGC-15302

P3

Active, not recruiting

Osteoarthritis

2024-03-06

34%

Recent News Events